Abstract: A measurement system and method tests for spurious emissions included in a signal transmitted from a mobile terminal in a shorter time than before. The system includes: a band division unit for dividing the measurement frequency band into a plurality of divided bands; a first spurious measurement control unit which causes a measurement device to measure the spurious emissions of the signal to be measured in each divided band and the peak power of the spear in each divided band; and a first pass/fail determination unit that determines whether or not pass determination criteria is satisfied. The first pass/fail determination unit determines whether the peak power does not exceed the threshold of the pass determination criteria in each divided band. The threshold value of the pass determination criteria is lower than the threshold of the standard determination criteria defined by the 3GPP standard.

Abstract: An alighting assistance device D of the present disclosure may be a device moving a driver seat rearward in a case where a determination may be made that an occupant seated on the driver seat of a vehicle alights. The device may include a height changer which changes a height of a steering wheel, a sitting height acquirer which acquires a sitting height of the occupant, and a steering wheel controller 33 as one example of a height controller which controls the height changer such that the height of the steering wheel becomes lower as the sitting height acquired by the sitting height acquirer may be higher in the case where a determination is made that the occupant alights.

Abstract: It is an object of the present invention to provide a Japanese encephalitis preventive agent and a Japanese encephalitis vaccine agent, which are capable of imparting sufficient immunity to humans, even if these agents are used at a lower dose than the dose of a Japanese encephalitis vaccine for subcutaneous injection, or at a smaller number of administrations than the number of administrations of a Japanese encephalitis vaccine for subcutaneous injection. According to the present invention, provided is a Japanese encephalitis preventive agent, comprising a microneedle array having a sheet portion and a plurality of needle portions present on the upper surface of the sheet portion, wherein the aforementioned needle portions contain or carry an inactivated Japanese encephalitis virus.

Abstract: A parallax calculating apparatus is provided with: a processor configured to perform, on each of a plurality of types of block shapes that are different from each other, (i) a parallax calculation process, (ii) a block group setting process, and (iii) a cost calculation process, by using a pair of images photographed by a stereo camera; and a selector configured to perform, on each of a plurality of pixels that constitute the image, a parallax selection process of setting a parallax value of a block in which a cost associated by the cost calculation process is minimum, as a parallax of a target pixel in which the parallax is to be obtained, from among a plurality of blocks, each of which includes the target pixel and which respectively correspond to the plurality of types of block shapes.

Abstract: A parallax calculating apparatus is provided with: a processor configured to perform, on each of a plurality of types of block shapes that are different from each other, (i) a parallax calculation process, (ii) a block group setting process, and (iii) a cost calculation process, by using a pair of images photographed by a stereo camera; and a selector configured to perform, on each of a plurality of pixels that constitute the image, a parallax selection process of setting a parallax value of a block in which a cost associated by the cost calculation process is minimum, as a parallax of a target pixel in which the parallax is to be obtained, from among a plurality of blocks, each of which includes the target pixel and which respectively correspond to the plurality of types of block shapes.

Abstract: The method of forming an oxidation resistant coating layer is for forming an oxidation resistant coating layer containing aluminum on a surface layer of a member (A) formed of metallic material. The method includes a plating treatment step (S1) of plating aluminum on a surface of the member (A) in a solvent, and a heat treatment step (S2) of heat-treating the member (A) whose surface has been plated by the plating treatment step (S1).

Abstract: The method of forming an oxidation resistant coating layer is for forming an oxidation resistant coating layer containing aluminum on a surface layer of a member (A) formed of metallic material. The method includes a plating treatment step (S1) of plating aluminum on a surface of the member (A) in a solvent, and a heat treatment step (S2) of heat-treating the member (A) whose surface has been plated by the plating treatment step (S1).

Abstract: An object is to find the minimum activity expression site of fibronectin, clarify the actions of this minimum unit in relation to opthalmological fields, and provide an opthalmological composition having this minimum unit as an effective component. This invention provides an opthalmological composition, in particular, a corneal disorder treatment agent containing the peptide, PHSRN (SEQ ID NO: 1) (Pro-His-Ser-Arg-Asn (SEQ ID NO: 1)), or Ac-Pro-His-Ser-Arg-Asn-NH2, which is a derivative thereof, or a salt thereof that is allowable as a medical drug as an effective component. The preferred dosage form is an ophthalmic formulation.

Abstract: An object is to find the minimum activity expression site of fibronectin, clarify the actions of this minimum unit in relation to opthalmological fields, and provide an opthalmological composition having this minimum unit as an effective component. This invention provides an opthalmological composition, in particular, a corneal disorder treatment agent containing the peptide, PHSRN (SEQ ID NO: 1) (Pro-His-Ser-Arg-Asn (SEQ ID NO: 1)), or Ac-Pro-His-Ser-Arg-Asn-NH2, which is a derivative thereof, or a salt thereof that is allowable as a medical drug as an effective component. The preferred dosage form is an ophthalmic formulation.

Abstract: An object is to find the minimum activity expression site of fibronectin, clarify the actions of this minimum unit in relation to ophthalmological fields, and provide a ophthalmological composition having this minimum unit as an effective component. This invention provides an ophthalmological composition, in particular, a corneal disorder treatment agent containing the peptide, PHSRN (SEQ ID NO: 1)(Pro-His-Ser-Arg-Asn (SEQ ID NO: 1)), or Ac-Pro-His-Ser-Arg-Asn-NH2, which is a derivative thereof, or a salt thereof that is allowable as a medical drug as an effective component. The preferred dosage form is an ophthalmic formulation.